CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback